Biomunex immunotherapy project awarded grant of close to €3m

Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.

Related Keywords

Switzerland ,France ,French ,Swiss ,Pierre Emmanuel Gerard ,Institut Curie , ,Paris Based Institut Curie ,Onward Therapeutics ,Markets Amp Regulations ,Pipelines ,Cell Amp Gene Therapies ,Immunotherapy ,Solid Tumor ,Antibodies ,T Cell ,